RxDoctor Payments Data

Mario Oliver, MD

Family Medicine · Murrieta, CANPI 1124327606

Payments from drug & device makers

$4,654in general payments, 2019–2025

Across 226 payments — averaging $20.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$803
  • Lilly USA, LLC$751
  • AstraZeneca$719
  • Boehringer Ingelheim$302
  • GSK$279
  • AbbVie$254
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$4,654100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,654 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$31,002
Medicare patients
99
Services billed
2,611

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide20$21,278
FarxigaDapagliflozin Propanediol18$16,240
JardianceEmpagliflozin17$13,263
Tresiba Flextouch U-200Insulin Degludec11$7,439
SymbicortBudesonide/Formoterol Fumarate12$4,696
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen60$2,444
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$2,341
Diclofenac Sodium12$2,287
Levothyroxine Sodium126$1,775
Atorvastatin Calcium206$1,395
Naproxen13$1,375
Gabapentin25$1,174
Albuterol Sulfate HfaAlbuterol Sulfate22$898
Tamsulosin Hcl56$786
ClopidogrelClopidogrel Bisulfate23$618

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$803$21,27820 claims
AstraZenecaFarxiga, Symbicort$719$20,93530 claims
Boehringer IngelheimJardiance$302$13,26317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Murrieta

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →